Global Gene Editing Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

November 2017 | 201 pages | ID: GBE4C55F2C7EN
Precision Business Insights (PBI)

Abstracts

Global Gene Editing Market

Gene editing or Genome editing is the type of genetic editing where DNA is inserted, replaced or deleted in the genome of an organism in order to treat a specific disease by using a molecular scissors or engineered nuclease. These nucleases create site-specific double-stranded breaks in desired locations in genome. The induced double-stranded breaks are repaired through nonhomologous end joining or homologous recombination resulting in targeted mutations (edits).

Rise in the prevalence rate of cancer & other genetic disorders, increasing preference in the personalized medicine, companies investments towards R&D, and growth of biotechnology and pharmaceutical industries, increase in private and public sector funding, rapid advancements in sequencing and gene editing technologies, applications in various drug discovery processes are some of the factors propelling the growth of the genome editing market. However, global gene editing market is hindered by stringent government regulations to approve gene mutation projects, ethical issues, unavailability of gene editing based therapeutics in the market and lack of awareness among people regarding the safety of genetic interventions.

The gene editing market segmented based upon applications, technology, end-user, products, and region.

On the basis of technology, global genome editing market is segmented as:

• Zinc Finger Nuclease (ZFN)
• Clustered regularly interspaced short palindromic repeats (CRISPR)
• Transcription activator-like effector nuclease (TALEN)
• Others

On the basis of application, global genome editing market is segmented as:

• Cell Line Editing
• Targeted gene mutation
• Animal Genome Editing
• Plant Genome Editing

On the basis of product type, global genome editing market is segmented as:

• Consumables
• Instruments and Software

On the basis of end-user, Global Genome Editing Market is segmented as:

• Pharmaceutical companies
• Biotechnology Companies
• Academics
• Clinical Research Organizations

Biotechnology and pharmaceutical sectors dominate gene editing market due to its applications in drug discovery and therapeutics. Rise in usage of CRISPR and ZFN, companies are investing in innovative research for development of novel gene editing techniques. Many players are adopting various strategies which include collaborations for R&D outsourcing, mergers and acquisitions, strategic or manufacturing activities are driving the growth of genome editing market. For instance, in 2014, Thermo Fisher acquired Life technologies, to create unbeatable leadership in life sciences, research, speciality diagnostics and applied markets.In 2014, Sigma-Aldrich Corporation (U.S.) entered into an agreement with Broad Institute of MIT and Harvard (U.S.) to use CRISPR technology. High growth potential in emerging regions provides lucrative opportunities to industry players.

On the basis of Geographical regions, the genome editing market categorized into five regions:, Europe, North America, Latin America, Asia Pacific, and Middle East & Africa. The gene editing market is dominated by North America due to the strong growth trend in the pharmaceuticals and biotechnology industries. Emerging economies of Asia Pacific and Latin America are expected to show significant growth in the gene editing market due to an increase in the number of laboratories in these regions and development of existing ones for automation of various instrumentation systems, the expansion of leading genome editing companies and increased R&D spending.

Some of the players in genome editing market are Cellectis S.A. (France), Applied Stemcell, Inc. (U.S.), Genscript (U.S.), Merck KGaA (Germany), Horizon Discovery Group plc,(U.K.), Origene Technologies, Inc. (U.S.), System Biosciences, Inc. (U.S.), Sangamo Therapeutics, Inc.(U.S.), Thermo Fisher Scientific (U.S), and Transposagen Biopharmaceuticals, Inc.(U.S.)

In July 2017, Cellectiswas granted the European Patent for the invention of the genetically engineering T-cells by adopting RNA-guided endonucleases, such as CRISPR associated protein 9 (Cas9) or Centromere and Promoter Factor 1(Cpf1 )

In July 2017 Sangamo Therapeutics, Inc. received the U.S.FDA Fast Track designation for in vivo genome editing product candidates SB-318 and SB-913 to treat Mucopolysaccharidosis Type I (MPS I) and MPS II

In November 2016, OriGene Technologies entered strategic agreement with EdiGene (Beijing, China) for the development of genome-wide knockout cells from laboratory cell lines which are commonly used

Report Outline:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL GENE EDITING MARKET INTRODUCTION

2.1. Global Gene Editing Market – Taxonomy
2.2. Global Gene Editing Market –Definitions
  2.2.1. Product
  2.2.2. Technology
  2.2.3. Application
  2.2.4. End-User

3. GLOBAL GENE EDITING MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Gene Editing Market Dynamics – Factors Impact Analysis
3.6. Global Gene Editing Market – Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan
  3.6.4. China
3.7. Global Gene Editing Market – Product Innovations

4. GLOBAL GENE EDITING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL GENE EDITING MARKET, BY PRODUCT, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Instruments and Software
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.1.3. Market Opportunity Analysis
5.2. Consumables
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.2.3. Market Opportunity Analysis

6. GLOBAL GENE EDITING MARKET FORECAST, BY TECHNOLOGY, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Zinc Finger Nuclease (ZFN)
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.1.3. Market Opportunity Analysis
6.2. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.2.3. Market Opportunity Analysis
6.3. Transcription Activator-Like Effector Nuclease (TALEN)
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.3.3. Market Opportunity Analysis
6.4. Others
  6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.4.3. Market Opportunity Analysis

7. GLOBAL GENE EDITING MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Cell Line Editing
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.1.3. Market Opportunity Analysis
7.2. Targeted gene mutation
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.2.3. Market Opportunity Analysis
7.3. Animal Genome Editing
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.3.3. Market Opportunity Analysis
7.4. Plant Genome Editing
  7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.4.3. Market Opportunity Analysis

8. GLOBAL GENE EDITING MARKET FORECAST, BY END-USER, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Pharmaceutical companies
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.1.3. Market Opportunity Analysis
8.2. Biotechnology Companies
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.2.3. Market Opportunity Analysis
8.3. Academics
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.3.3. Market Opportunity Analysis
8.4. Clinical Research Organizations
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.4.3. Market Opportunity Analysis

9. GLOBAL GENE EDITING MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. North America
  9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  9.1.3. Market Opportunity Analysis
9.2. Europe
  9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
  9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  9.3.3. Market Opportunity Analysis
9.4. Latin America
  9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
  9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  9.5.3. Market Opportunity Analysis
9.6. Global Gene Editing Market - Opportunity Analysis Index, By Product, Technology, Application, End-User, and Region, 2017 – 2023

10. NORTH AMERICA GENE EDITING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.1.1. Instuments and Software
    10.1.1.2. Consumables
  10.1.2. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Zinc Finger Nuclease (ZFN)
    10.1.2.2. Clustered regularly interspaced short palindromic repeats (CRISPR)
    10.1.2.3. Transcription activator-like effector nuclease (TALEN)
    10.1.2.4. Others
  10.1.3. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Cell Line Editing
    10.1.3.2. Targeted gene mutation
    10.1.3.3. Animal Genome Editing
    10.1.3.4. Plant Genome Editing
  10.1.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Pharmaceutical Companies
    10.1.4.2. Biotechnology Companies
    10.1.4.3. Academics
    10.1.4.4. Clinical Research Organizations
  10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    10.1.5.1. U.S.
    10.1.5.2. Canada
  10.1.6. North America Gene Editing Market - Opportunity Analysis Index, By Product Analysis, By Technology, By Application, By End-User, and Country, 2017 – 2023
  10.1.7. North America Gene Editing Market Dynamics – Trends

11. EUROPE GENE EDITING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.1.1.1. Instuments and Software
    11.1.1.2. Consumables
  11.1.2. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Zinc Finger Nuclease (ZFN)
    11.1.2.2. Clustered regularly interspaced short palindromic repeats (CRISPR)
    11.1.2.3. Transcription activator-like effector nuclease (TALEN)
    11.1.2.4. Others
  11.1.3. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Cell Line Editing
    11.1.3.2. Targeted gene mutation
    11.1.3.3. Animal Genome Editing
    11.1.3.4. Plant Genome Editing
  11.1.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.4.1. Pharmaceutical Companies
    11.1.4.2. Biotechnology Companies
    11.1.4.3. Academics
    11.1.4.4. Clinical Research Organizations
  11.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.5.1. Germany
    11.1.5.2. UK
    11.1.5.3. France
    11.1.5.4. Spain
    11.1.5.5. Italy
    11.1.5.6. Russia
    11.1.5.7. Poland
    11.1.5.8. Rest of Europe
  11.1.6. Europe Gene Editing Market - Opportunity Analysis Index, By Product Analysis, By Technology, By Application, By End-User and Country, 2017 – 2023
  11.1.7. Europe Gene Editing Market Dynamics – Trends

12. ASIA-PACIFIC GENE EDITING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.1.1. Instuments and Software
    12.1.1.2. Consumables
  12.1.2. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Zinc Finger Nuclease (ZFN)
    12.1.2.2. Clustered regularly interspaced short palindromic repeats (CRISPR)
    12.1.2.3. Transcription activator-like effector nuclease (TALEN)
    12.1.2.4. Others
  12.1.3. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Cell Line Editing
    12.1.3.2. Targeted gene mutation
    12.1.3.3. Animal Genome Editing
    12.1.3.4. Plant Genome Editing
  12.1.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Pharmaceutical Companies
    12.1.4.2. Biotechnology Companies
    12.1.4.3. Academics
    12.1.4.4. Clinical Research Organizations
  12.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    12.1.5.1. Japan
    12.1.5.2. China
    12.1.5.3. India
    12.1.5.4. ASEAN
    12.1.5.5. Australia & New Zealand
    12.1.5.6. Rest of Asia-Pacific
  12.1.6. Asia-Pacific Gene Editing Market - Opportunity Analysis Index, By Product Analysis, By Technology, By Application, By End-User and Country, 2017 – 2023
  12.1.7. Europe Gene Editing Market Dynamics – Trends

13. LATIN AMERICA GENE EDITING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.1.1. Instuments and Software
    13.1.1.2. Consumables
  13.1.2. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.2.1. Zinc Finger Nuclease (ZFN)
    13.1.2.2. Clustered regularly interspaced short palindromic repeats (CRISPR)
    13.1.2.3. Transcription activator-like effector nuclease (TALEN)
    13.1.2.4. Others
  13.1.3. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Cell Line Editing
    13.1.3.2. Targeted gene mutation
    13.1.3.3. Animal Genome Editing
    13.1.3.4. Plant Genome Editing
  13.1.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.4.1. Pharmaceutical Companies
    13.1.4.2. Biotechnology Companies
    13.1.4.3. Academics
    13.1.4.4. Clinical Research Organizations
  13.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.5.1. Brazil
    13.1.5.2. Mexico
    13.1.5.3. Argentina
    13.1.5.4. Venezuela
    13.1.5.5. Rest of Latin America
  13.1.6. Latin America Gene Editing Market - Opportunity Analysis Index, By Product Analysis, By Technology, By Application, By End-User and Country, 2017 – 2023
  13.1.7. Latin America Gene Editing Market Dynamics – Trends

14. MIDDLE EAST AND AFRICA GENE EDITING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  14.1.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    14.1.1.1. Instuments and Software
    14.1.1.2. Consumables
  14.1.2. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.2.1. Zinc Finger Nuclease (ZFN)
    14.1.2.2. Clustered regularly interspaced short palindromic repeats (CRISPR)
    14.1.2.3. Transcription activator-like effector nuclease (TALEN)
    14.1.2.4. Others
  14.1.3. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.3.1. Cell Line Editing
    14.1.3.2. Targeted gene mutation
    14.1.3.3. Animal Genome Editing
    14.1.3.4. Plant Genome Editing
  14.1.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.4.1. Pharmaceutical Companies
    14.1.4.2. Biotechnology Companies
    14.1.4.3. Academics
    14.1.4.4. Clinical Research Organizations
  14.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    14.1.5.1. Gulf Cooperation Council (GCC) Countries
    14.1.5.2. Israel
    14.1.5.3. South Africa
    14.1.5.4. Rest of MEA
  14.1.6. MEA Gene Editing Market - Opportunity Analysis Index, By Product Analysis, By Technology, By Application, By End-User and Country, 2017 – 2023
  14.1.7. MEA Gene Editing Market Dynamics – Trends

15. COMPETITION LANDSCAPE

15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  15.2.1. Cellectis S.A. (France)
  15.2.2. Applied Stemcell, Inc. (U.S.)
  15.2.3. Genscript (U.S.)
  15.2.4. Merck KGaA (Germany)
  15.2.5. Horizon Discovery Group plc(U.K.
  15.2.6. Origene Technologies, Inc. (U.S.)
  15.2.7. System Biosciences, Inc. (U.S.)
  15.2.8. Sangamo Therapeutics, Inc.(U.S.)
  15.2.9. Thermo Fisher Scientific (U.S)
  15.2.10. Transposagen Biopharmaceuticals, Inc.(U.S.)

16. RESEARCH METHODOLOGY

17. KEY ASSUMPTIONS AND ACRONYMS